BioTek Instruments embarks on major site expansion
BioTek Instruments celebrated the start of a $4 million, 22,000 square foot facility expansion during a company-wide event on Monday, July 18, featuring honorable guests Vermont Senator Patrick Leahy, Congressman Peter Welch, Governor Peter Shumlin, and Lt. Governor Phil Scott. The increased space will be used to support the Company’s rapidly growing manufacturing and design needs, and once completed at the end of 2016, will also add a number of new jobs to the local economy.
“As a global company, BioTek has a reach that spans borders. Briar and Adam [Alpert] have chosen to grow their company right here, at home in Vermont,” commented Senator Leahy at the ceremony. “As I continue to work at the federal level to support Vermont businesses, and on increased access to capital and investment in our state’s infrastructure, their decision serves as an inspiration and a model to many other Vermont businesses that also plan to grow.” He continued, “Vermont is a great place to invest, grow a business and raise a family, and BioTek is an example of that.”
“Our truest successes are not defined by dollars, but rather by making shared positive impacts throughout our state, our country and across the entire world; and I’m proud of what we have accomplished together,” added Briar Alpert, BioTek President and CEO. “Today, our world-renowned products are used to find cures and treatments for a wide array of diseases and disorders, to ensure the safety and efficacy of resources we depend upon, and to uncover new uses for existing materials. We develop and manufacture all of these products right here in Vermont, and we’re a working example of home-grown success reaching a global scale.”
Other news from the department manufacturing

Get the life science industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.
More news from our other portals
Last viewed contents
Chiron and XOMA announce initiation of phase I clinical trial fpr CHIR-12.12 in multiple myeloma - Second clinical trial evaluating oncology drug candidate begins
Combinatorial_chemistry
